Specific cohorts have demonstrated a substantial reduction of 25% in IGF-1 levels and a 40% reduction in IGFBP-3 levels in stroke survivors, compared to healthy controls, indicating a severe deficit in anabolic signaling. This evidence concerns the gene IGFBP3 and Stroke.